Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Consensus Rating of “Moderate Buy” by Brokerages

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has been given a consensus rating of “Moderate Buy” by the seven brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $43.00.

LYEL has been the topic of several research analyst reports. Robert W. Baird set a $49.00 target price on shares of Lyell Immunopharma and gave the stock an “outperform” rating in a report on Thursday, April 30th. Zacks Research upgraded shares of Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th. Needham & Company LLC reissued a “buy” rating and set a $44.00 price objective on shares of Lyell Immunopharma in a research report on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Tuesday, April 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Lyell Immunopharma in a research report on Tuesday, June 9th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC raised its position in Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after acquiring an additional 154,327 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Lyell Immunopharma in the 2nd quarter valued at about $94,000. Bridgeway Capital Management LLC bought a new position in shares of Lyell Immunopharma in the 2nd quarter valued at about $159,000. BBR Partners LLC acquired a new position in shares of Lyell Immunopharma during the 4th quarter worth about $210,000. Finally, Walleye Capital LLC acquired a new position in shares of Lyell Immunopharma during the 2nd quarter worth about $258,000. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Stock Down 4.1%

Shares of NASDAQ LYEL opened at $13.32 on Friday. The company’s fifty day moving average is $14.75 and its 200-day moving average is $20.44. The stock has a market cap of $326.34 million, a price-to-earnings ratio of -0.97 and a beta of -0.06. Lyell Immunopharma has a twelve month low of $9.24 and a twelve month high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, meeting analysts’ consensus estimates of ($1.10). Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. The business had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.00 million. On average, research analysts anticipate that Lyell Immunopharma will post -7.87 EPS for the current fiscal year.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.